THU0219 The Infliximab Dose Increase is Not Correlated with Clinical Improvement in RA Patients

• Published in: Annals of the rheumatic diseases Vol. 72; no. Suppl 3; p. A238
• Main Authors: López-Casla, M. T., Pascual-Salcedo, D., Plasencia, C., Alcozer, P., García-Carazo, S., Bonilla, G., Villalba, A., Peiteado, D., Arribas, F., Martín-Mola, E., Balsa, A.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2013; BMJ Publishing Group LTD

Background The anti-TNF therapy is an effective treatment in RA patients, however a considerable percentage of patients develop clinical inefficacy (primary or secondary); part of which can be explained by the development of antibodies to infliximab (ATI). In some patients, a dose increase is often...